As already stated in the previous article “News from ECTRIMS (1)“: We have now become very good at controlling focal inflammation in MS – that is, the inflammatory response triggered by the influx of peripheral
Continue reading
There has been a lot of progress in the development of MS therapy, since the first interferon for multiple sclerosis came on the market in the mid-90s. There are now almost 20 immunomodulatory agents approved.
Continue reading
Vidofludimus Calcium (IMU838) is a new, selective inhibitor of the enzyme dihydroorotate dehydrogenase (DHODH) from the biotech company Immunic Therapeutics. The manufacturer is currently testing it in patients with relapsing-remitting multiple sclerosis in a phase
Continue reading
The treatment options for progressive MS are limited – so interest was high when the study data on the use of high-dose biotin in progressive MS was first presented at the American Neurology Congress in
Continue reading
There is still a lot of confusion regarding the assignment to a specific MS course type. Generally, a distinction is made between relapsing (RMS), secondary chronic progressive (SPMS) and primary chronic progressive (PPMS) multiple sclerosis.
Continue reading
Unsere Website verwendet Cookies und sammelt dabei Informationen über Ihren Besuch, um unsere Website zu verbessern (durch Analyse), Ihnen Social Media-Inhalte und relevante Werbung anzuzeigen. Weitere Informationen finden Sie auf unserer Seite . Sie können zustimmen, indem Sie auf die Schaltfläche "Akzeptieren" klicken.
Cookie-Einstellungen
Unten können Sie auswählen, welche Art von Cookies Sie auf dieser Website zulassen. Klicken Sie auf die Schaltfläche "Cookie-Einstellungen speichern", um Ihre Auswahl zu übernehmen.
Dieser Inhalt ist gesperrt. Akzeptieren Sie Cookies in der Kategorie '%CC%', um diesen Inhalt anzuzeigen.
